Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AX251 LAI in Schizophrenia
NCT07484204Phase 1Recruiting
- Sponsor
- Anxo Pharmaceutical
- Start
- Sep 2026
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of AX251 in schizophrenia (4 arms), sponsored by Anxo Pharmaceutical. Primary endpoint: Pharmacokinetic Parameter at Day 70. Started Sep 2026; status: recruiting.
02
Drugs
AX251
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07484204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07484204.